RTP Mobile Logo
Data + Perspectives: Clinical Investigators Explore the Emerging Role of PARP Inhibition in the Management of Breast Cancer
Released February 2018

Proceedings from a satellite symposium during the 40th annual San Antonio Breast Cancer Symposium. Featuring perspectives from Drs Susan M Domchek, Karen A Gelmon, Mark Robson and Hope S Rugo. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer (BC).

    BRCA1 and BRCA2 are not new entities, and it has been appreciated for some time that individuals harboring these abnormalities have increased susceptibility to developing BC as well as ovarian cancer and several other common tumor types. In fact, according to recent estimates, 55% to 65% of women who inherit a harmful BRCA1 mutation and approximately 45% of women who inherit a BRCA2 mutation will develop BC by age 70. Until recently, patients with BRCA1/2 mutations were largely cared for in the same manner as those without these genomic abnormalities. However, the promising findings observed with the use of PARP inhibitors as monotherapy or in combination with other agents led to the activation of a number of trials designed to definitively measure their efficacy and safety in large populations, which has most recently resulted in the first FDA approval for an agent in this class in BC. Owing to this approval and the host of ongoing clinical trials evaluating PARP inhibitors across a variety of settings, it is clear that oncologists in practice need to rapidly acquire knowledge regarding the efficacy and tolerability of this class of agents in order to effectively use them, both on and off protocol, in their clinics.

    These video proceedings from a CME symposium held during the 2017 San Antonio Breast Cancer Symposium feature discussions with leading BC researchers regarding actual cases of patients who underwent treatment with a PARP inhibitor and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to improve clinicians’ knowledge of recent data related to this rapidly evolving area of BC treatment.


    • Recall available guideline recommendations regarding the indications for BRCA mutation testing for patients diagnosed with BC, and use the results of this analysis to inform protocol and nonprotocol treatment decision-making.
    • Understand the biologic rationale for the investigation of PARP inhibition as monotherapy or in combination with other systemic approaches for patients with BC, and use this insight to prioritize clinical trial opportunities for appropriate individuals eligible for participation.
    • Recall efficacy data with the use of PARP inhibition in patients with metastatic BC harboring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these findings on clinical care.
    • Educate patients regarding the side effects associated with the use of PARP inhibitors, and develop preventive and emergent strategies to reduce or ameliorate these toxicities.
    • Describe mechanisms of acquired tumor resistance to PARP inhibitors, and identify investigational therapeutic opportunities to circumvent this process.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Susan M Domchek, MD
    Director, MacDonald Women’s Cancer Risk Evaluation Center
    Executive Director, Basser Center for BRCA
    Basser Professor in Oncology
    Perelman School of Medicine
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Honoraria: AstraZeneca Pharmaceuticals LP, Clovis Oncology.

    Karen A Gelmon, MD
    Professor, Medicine
    Head, Division of Medical Oncology
    University of British Columbia
    Medical Oncologist, BC Cancer Agency
    Vancouver Cancer Centre
    Vancouver, Canada

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Lilly, Merck, Novartis, Pfizer Inc.

    Mark Robson, MD
    Clinic Director, Clinical Genetics Service
    Associate Attending Physician, Clinical Genetics and Breast Cancer Medicine
    Associate Member, Memorial Sloan Kettering Cancer Center
    Associate Professor of Medicine, Weill Medical College of Cornell University
    New York, New York

    Advisory Committee, Consulting Agreement and Contracted Research: AstraZeneca Pharmaceuticals LP.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Amgen Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Roche Laboratories Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Myriad Genetic Laboratories Inc, Pfizer Inc and Tesaro Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2018
    Expiration date: February 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):